alexa Chimigen? HBV Therapeutic Vaccine: A Novel Dendritic Cell Receptor-targeted Immunotherapy For Treating Chronic Hepatitis B Virus Infection
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Rajan George
Accepted Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.022
Abstract
Worldwide, there are more than 370 million people who are chronically infected with Hepatitis B Virus (HBV) and at the risk of developing liver cirrhosis and hepatocellular carcinoma. More than one million people die every year due to complications of HBV-related chronic liver disease. Antiviral agents can efficiently control virus replication, but rarely eliminate the virus and the emergence of mutant strains of the virus is a major disadvantage. Host immune help is needed in the complete elimination of viral infection. Immunotherapeutic approaches to treating chronic HBV infection is a major unmet medical need, and currently none is available. Chimigen? Vaccines are a new class of chimeric molecules with functional attributes of both antigen and antibody. These molecules target the host immune system using specific receptors on dendritic cells (DCs), are taken up and processed for antigen presentation through both MHC class I and class II pathways to elicit cellular and humoral immune responses. Chimigen? HBV (S1/S2-core) Vaccine, a fusion protein of HBV S1 and S2 surface antigen fragments, Core and a murine Fc fragment was produced in insect cells. In ex vivo assays using human PBMC-derived DC/T cell assays, the vaccine, following binding to CD32 and CD206 receptors, was internalized and activated T cells (CD8+/CD4+) which produce IFN-γ, TNF-α, GrB, Pfn and are capable of killing target cells. These effects were also shown in assays using HBV-infected individuals. In addition, the vaccine showed production of T responder cells which are capable of removing T regulatory cells which induce tolerance to HBV in the host. In animal studies, the vaccine elicited T cell and B cell activation, induced the production of inflammatory cytokines in the liver of HBV-transgenic animals.
Biography
Rajan George is President & Chief Scientific Officer at Akshaya Bio Inc., Edmonton, Canada. Previously, CTO, Paladin Biosciences and Senior VP of ViRexx Medical Corp. Received Ph.D degree in Biochemistry from the Indian Institute of Science (Bangalore, India). Had Postdoctoral training at the University of Wisconsin in Madison, WI, USA and at the University of Alberta (Edmonton, Alberta, Canada). Holds Adjunct Faculty appointment in the Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. Lead inventor of Chimigen? Technology with more than 16 issued patents.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords